Viewing nowLerspo Tablet (Terbinafine Hydrochloride)
Terbinafine Hydrochloride 140.625mg
Tablet · Prescription medication
Hawon Pharmaceutical Co., Ltd.

MFDS item code 200102846 · Notified 2001.09.24 · Insurance code 651500290
Treatment of onychomycosis and cutaneous fungal infections (e.g., tinea pedis, tinea corporis, and tinea capitis)
This medication is used for the treatment of dermatophytosis such as tinea pedis, tinea corporis, tinea capitis, and onychomycosis in adults. It is used for the treatment of tinea capitis in children.
1. Adults Administer terbinafine at a dose of 125 mg twice daily or 250 mg once daily. The duration of treatment according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Treatment is usually given for 6 weeks~3 months. For infections of the fingernails or relatively small toes, or in younger patients, the treatment duration may be shortened to 3 months or less. A treatment duration of 3 months is usually sufficient for toenail infections, although some patients may require 6 months or longer. Treatment may take longer in patients with slow nail growth. 3. Patients with renal impairment For patients with creatinine clearance below 50 mL/min, reduce the daily dose by 1/2.
2. Children: Administer to children aged 2 years or older. Administration is not recommended in children under 2 years of age because there is no experience with use in this age group. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of infection, treatment should be given regularly and for the prescribed duration. Body weight below 20 kg (under 5 years): Administer 62.5 mg once daily. Because experience with use is limited, determine whether to administer after considering the benefits and risks of treatment. Body weight 20~40 kg (5~12 years): Administer 125 mg once daily. Body weight over 40 kg (over 12 years): Administer 250 mg once daily.
This medication should generally not be used in patients with chronic liver disease or active liver disease. Liver function tests must be conducted before administration, and liver function should be monitored regularly during treatment. If symptoms of liver dysfunction appear, the medication should be discontinued immediately and medical advice sought. Patients with blood disorders or severe renal failure, children under 2 years old, and breastfeeding women should not take this medication. Patients with a history of allergic reactions to this medication should also avoid it. Elderly patients or those with impaired kidney function should use this medication with caution, and caution is also necessary for children with low body weight. This medication may rarely cause severe skin reactions, so if skin rash or unusual symptoms appear, the medication should be discontinued immediately. Musculoskeletal symptoms such as muscle pain or joint pain may occur, and if symptoms are severe, inform a doctor. Neuropsychiatric symptoms such as dizziness, headache, and taste disturbances have also been reported, so it is advisable to avoid driving or operating machinery if such symptoms are present. This medication may interact with other drugs, so if other medications are being taken, it is essential to inform a doctor or pharmacist. Women who are pregnant or may become pregnant should use this medication with caution, and breastfeeding women should stop breastfeeding while using this medication. In cases of overdose, symptoms such as headache, nausea, abdominal pain, and dizziness may appear, so immediate medical attention should be sought if these symptoms occur. This medication should be stored out of reach of children and kept at room temperature away from direct sunlight.
Liver failure, hepatitis, cholestasis, jaundice, rash, skin itching, fever, nausea, vomiting, loss of appetite, malaise, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, petechiae, leukopenia, anemia, rash, itching, photosensitivity reaction, mucocutaneous syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, blistering dermatitis, psoriasis-like rash, psoriasis aggravation, hair loss, musculoskeletal reactions, arthralgia, myalgia, weakness, elevated CPK, increased serum myoglobin, increased urinary myoglobin, hypotension, dyspnea, chest tightness, urticaria, erythema, facial edema, lymphangioma, abdominal distension, decreased appetite, dyspepsia, mild abdominal pain, diarrhea, abdominal discomfort, thirst, vomiting, glossitis, depression, anxiety, headache, loss of taste, taste disorders, dizziness, drowsiness, sensory disturbances, sensory impairment, decreased attention, insomnia, elevated BUN, polyuria, visual disturbances, tinnitus, anaphylactic reaction, angioedema, systemic lupus erythematosus, elevated total cholesterol, elevated triglycerides, malaise, tongue discoloration, palpitations, edema, menstrual irregularities, paralysis, systemic disorders, fever, fatigue, weight loss, anaphylactic reaction, serum sickness-like reaction, blurred vision, decreased vision, hearing loss, auditory disorders, vasculitis, permanent anosmia, hyposmia, eosinophilia with systemic symptoms and drug rash, pancreatitis, rhabdomyolysis, influenza-like illness, increased blood creatine phosphokinase, headache, nausea, upper abdominal pain, dizziness
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container that prevents air exposure and is safe at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness.
White to yellowish round tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowTerbinafine Hydrochloride 140.625mg
Tablet · Prescription medication
Hawon Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
GP Therapeutics Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Hutex Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Anguk Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Medica Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Gyeongnam Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Daehwa Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.